DeepMed Research

Shanghai Jiaotong Medical University Attached Ruijin Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma

Phase 2

Recruiting

Conditions: T Cell Lymphoma

Interventions: Drug: Chidamide combined with BEAM

First Posted Date: 2022-05-10

Last Posted Date: 2022-09-29

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 23

Registration Number: NCT05367856

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Immune Function in Elderly Patients With Mild to Moderate COVID-19 on Hemodialysis

Not Applicable

Conditions: COVID-19
Hemodiafiltration

Interventions: Dietary Supplement: Oral nutritional supplement
Behavioral: Nutrition consultation

First Posted Date: 2022-05-09

Last Posted Date: 2022-05-09

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 112

Registration Number: NCT05366205

Genotype-guided Treatment in DLBCL

Phase 3

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Orelabrutinib
Drug: Lenalidomide
Drug: Decitabine

First Posted Date: 2022-04-28

Last Posted Date: 2023-03-24

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 1100

Registration Number: NCT05351346

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Zanubrutinib plus R-ICE
Drug: Decitabine plus R-ICE
Drug: Chidamide plus R-ICE
Drug: Tofacitinib plus R-ICE
Drug: Pomalidomide plus R-ICE

First Posted Date: 2022-04-27

Last Posted Date: 2024-10-23

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 76

Registration Number: NCT05348213

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma

Phase 3

Recruiting

Conditions: Primary Central Nervous System Lymphoma

Interventions: Drug: Orelabrutinib

First Posted Date: 2022-04-19

Last Posted Date: 2022-04-19

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 174

Registration Number: NCT05334238

Locations: 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China

Long Term Prospective Study of Tai Chi Intervention to Prevent MCI From Conversion to Dementia

Not Applicable

Not yet recruiting

Conditions: Mild Cognitive Impairment

Interventions: Behavioral: Tai chi training
Behavioral: Group activity

First Posted Date: 2022-04-05

Last Posted Date: 2022-08-01

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 206

Registration Number: NCT05310890

Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance

Not Applicable

Conditions: Diabetes

Interventions: Drug: Compound Danshen Dropping Pills
Drug: Placebo

First Posted Date: 2022-03-25

Last Posted Date: 2022-03-25

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 120

Registration Number: NCT05295329

Locations: 🇨🇳
Long March Hospital Affiliated to Naval Medical College, Shanghai, Shanghai, China
🇨🇳
Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai, Shanghai, China
🇨🇳
Renji Hospital Affiliated to Medical College of Shanghai Jiaotong University, Shanghai, Shanghai, China

and more 4 locations

Neuroinflammatory PET Imaging in Autoimmune Encephalomyelitis

Not Applicable

Recruiting

Conditions: Autoimmune Encephalomyelitis

Interventions: Diagnostic Test: 18F-DPA-714 PET

First Posted Date: 2022-03-24

Last Posted Date: 2023-04-18

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 100

Registration Number: NCT05293405

Locations: 🇨🇳
Ruijin Hospital, Shanghai, China

Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients

Phase 3

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: adjuvant concurrent chemoradiotherapy
Radiation: radiotherapy

First Posted Date: 2022-03-14

Last Posted Date: 2022-09-16

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 340

Registration Number: NCT05277688

Locations: 🇨🇳
Ruijin Hospital, Shanghai jiaotong univestigy school of medicine, Shanghai, Shanghai, China

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)

Phase 2

Recruiting

Conditions: Gastrointestinal Tumors

Interventions: Drug: Anlotinib + Oxaliplatin + Capecitabine
Drug: Anlotinib + Cisplatin + Paclitaxel/ Docetaxel
Drug: Anlotinib + Standard first-line chemotherapy

First Posted Date: 2022-03-02

Last Posted Date: 2023-11-28

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 116

Registration Number: NCT05262335

Locations: 🇨🇳
Affiliated Hospital of Jiannan University, Wuxi, Jiangsu, China
🇨🇳
Wuxi Branch of Rujin Hospital, Wuxi, Jiangsu, China
🇨🇳
Jiading Cental Hospital Shanghai University of Medicine & Health Sciences, Shanghai, China

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy